CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.
Presented by CURE®, a collection of resources that provide information and support for patients with squamous cell carcinoma and the professionals who treat them.
May 25th 2022
Patients can still talk to their clinicians about enrolling in a sub-study of the FIRELIGHT-1 trial, analyzing tovorafenib plus pimasertib in progressive or refractory solid tumors with MAPK pathway aberrations.
May 20th 2022
From PGA Tour golfer Justin Thomas’ new sun-protection line to soap opera actress Marnie Schulenburg’s breast cancer death and the first child to receive CAR-T cell therapy celebrating 10 years cancer-free, here’s what’s happening in the cancer space this week.
May 13th 2022
I like to think that cancer advocates live the motto of the postal service, “Neither snow nor rain nor heat nor gloom of night stays these couriers from their swift completion of their appointed rounds.”
May 12th 2022
The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.
April 19th 2022
Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.
April 17th 2022
Upon reflecting on my late wife's cancer experience, one of my major regrets is not properly saying goodbye.
April 14th 2022
Compared with Yervoy alone, the use of Yervoy plus Opdivo was associated with a significant survival benefit as a second-line treatment in patients with previously treated advanced melanoma, a type of skin cancer.
April 7th 2022
A phase 2 trial will investigate LTX-315 in patients with basal cell carcinoma, the most common form of skin cancer.
March 30th 2022
It is expected that up to 18 patients with leptomeningeal metastases — a serious form of cancer that has spread from its original location to an area surrounding the brain and spinal cord — will receive treatment with the investigational drug.
March 25th 2022
At first, I struggled to keep up with the scientific jargon being presented at a cancer conference, but eventually I hit my stride and now I leave these events with a renewed sense of inspiration.
March 23rd 2022
Patients with stage 3 melanoma, a type of skin cancer, that has metastasized to the lymph nodes may benefit from skipping lymph node removal surgery and receiving treatment with adjuvant therapy, although more research is needed in this area.
March 22nd 2022
The use of bempegaldesleukin and Opdivo failed to meet its goal of significantly improving progression-free survival and responses to treatment, compared with Opdivo alone in patients with previously untreated unresectable or metastatic melanoma, according to data from an initial analysis of the phase 3 PIVOT IO-001 study.
March 19th 2022
The FDA’s decision to greenlight Opdualag is based on data that showed that the combination more than doubled survival without disease progression when compared with Opdivo in patients with previously untreated metastatic or unresectable melanoma, a type of skin cancer.
March 16th 2022
The findings, according to the study’s lead author, justify the use of Opdivo plus relatlimab as a new treatment option for patients with advanced melanoma, a form of skin cancer.
Recent research has demonstrated the ability of immunotherapy combinations to target advanced melanoma.
March 14th 2022
When two small spots appeared on my face, I couldn’t help but wonder if they might be cancerous. Had I failed to protect my skin with a hat or sunscreen? Suddenly, I was cancerphobic.
March 10th 2022
Aesthetic appearances, according to an expert at the UCSF, are often important for patients following the surgical treatment of cancer. Advancements in this space over the past 20 years have allowed many to patients to look as normal as possible.
March 7th 2022
The time patients with resected melanoma, a type of skin cancer, lived without their disease spreading to distant organs improved drastically after treatment with Keytruda.
March 2nd 2022
The number of people developing leptomeningeal disease is increasing for the same reason that diagnoses of brain metastases are on the rise: People are living longer, giving cancer more time to spread.
March 1st 2022
Better therapies are on the horizon for cancer that has spread to the brain, including a clinical trial that matches patients with treatments based on unique genetic changes in brain metastases.
February 22nd 2022
The goal of the phase 2 trial is to study the safety and efficacy of ASP-1929, a photoimmunotherapy with fluorescence imaging, in patients with head and neck or skin cancer.
February 11th 2022
I learned that a more prominent obstacle that we need to navigate is getting past the assumption that having a darker skin tone protects people from skin cancer.
January 28th 2022
Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.
January 26th 2022
Kimmtrak is the first-ever drug to be granted FDA approval for this patient population of HLA-A*02:01-positive metastatic or unresectable uveal melanoma.
January 25th 2022
Patients with metastatic cutaneous squamous cell carcinoma achieved promising response rates after treatment with cosibelimab. If approved, drug developers are hoping to offer cosibelimab as a more affordable immunotherapy option for this patient population.
January 14th 2022
From the deaths of singer Ronnie Spector and famed cancer researcher Beatrice Mintz to a patient who became his own biggest advocate after a stranger noticed a suspicious spot on his back, here’s what’s happening in the cancer landscape this week.
January 10th 2022
Patients with melanoma who consumed a high-fiber diet may have a better response to immunotherapy, although the benefit was not as great if the fiber was obtained via probiotic supplements.
The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.
January 7th 2022
Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.
January 6th 2022
Certain allergy medications like Zyrtec and Claritin may be the key for more patients to tolerate immunotherapy for several cancer types.
The Gift of a Question in Cancer Care
Bringing Hope and Healing to Patients With Cancer
Discussing the Importance of Genetic Counseling in Women’s Cancer
Addressing Barriers to Care, Improving Access in Women’s Cancers